

New and Emerging Technologies and Other Non-Covered Services

MEDICAL POLICY NUMBER: 23

| | | |
|-----------------------------------|-------------------------------------|----|
| Effective Date: 12/1/2023 | COVERAGE CRITERIA | 2 |
| Last Review Date: 10/2023 | POLICY CROSS REFERENCES..... | 2 |
| Next Annual Review: 1/2024 | REGULATORY STATUS..... | 3 |
| | CLINICAL EVIDENCE REVIEW | 3 |
| | BILLING GUIDELINES AND CODING | 3 |
| | POLICY REVISION HISTORY..... | 32 |

INSTRUCTIONS FOR USE: Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

SCOPE: Providence Health Plan, Providence Health Assurance, and Providence Plan Partners as applicable (referred to individually as “Company” and collectively as “Companies”).

PLAN PRODUCT AND BENEFIT APPLICATION

Commercial

Medicaid/OHP*

Medicare**

*Medicaid/OHP Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

See Guideline Notes 172 and 173 of the OHP Prioritized List of Health Services for guidance on New and Emerging Technology. In the absence of OHP guidance, PHA will follow this policy.

**Medicare Members

This Company policy may be applied to Medicare Plan members only when directed by a separate Medicare policy. Note that investigational services are considered “**not medically necessary**” for Medicare members.

COVERAGE CRITERIA

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding each of the medical technologies listed in the CPT/HCPCS CODE section below. The evidence was determined to be insufficient to support the clinical utility, diagnostic efficacy, and/or safety of these technologies. Additional high-quality studies are needed to establish the long-term efficacy, durability, and safety of these technologies for any condition; therefore, all the following medical services listed in the CPT/HCPCS CODE section below are considered **investigational or not medically necessary**.

POLICY CROSS REFERENCES

None

The full Company portfolio of current Medical Policies is available online and can be [accessed here](#).

REGULATORY STATUS

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Approval or clearance by the Food and Drug Administration (FDA) does not in itself establish medical necessity or serve as a basis for coverage. Therefore, this section is provided for informational purposes only.

CLINICAL EVIDENCE REVIEW

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding each of the medical technologies listed below in the CPT/HCPCS CODE section above. The evidence was insufficient to support the clinical utility, diagnostic efficacy, and/or safety of these technologies. Evidence reviews and summaries for each technology addressed in this policy may be made available upon request.

BILLING GUIDELINES AND CODING

| CODES* | | |
|------------------|---|--|
| Code | Description | Manufacturer & Device Name (if applicable) |
| CPT CODES | | |
| 0002U | Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps | PolypDX™ by Atlantic Diagnostic Laboratories, LLC, and Metabolomic Technologies Inc. |
| 0025U | Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative | UrSure by UrSure, Inc. |
| 0407U | Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function | IntelxDKD by Renalytix Inc. |
| 0412U | Beta amyloid, Aβ42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology | PreclivityAD blood test by C2N Diagnostics |
| 0414U | Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, | LungOI by Imagene |

| | | |
|-------|---|---|
| | if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker | |
| 0416U | Infectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms, including identification of 20 associated antibiotic-resistance genes, if performed, multiplex amplified probe technique, urine | Genetworx UTI with ABR by RCA Laboratory Services |
| 0418U | Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score | PreciseDx Breast Biopsy Test, by PreciseDx Inc |
| 0054U | Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service | AssuranceRX Micro Serum Test by Firstox™ |
| 0058U | Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative | Merkel SmT Oncoprotein Antibody Titer, University of Washington Department of Laboratory Medicine |
| 0059U | Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative | |
| 0061U | Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis | Spatial Frequency Domain Imaging (SFDI) by Modulated Imaging, Inc. |
| 0086U | Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility | Accelerate PhenoTest™ BC kit by Accelerate Diagnostics, Inc. |
| 0095U | Eosinophilic esophagitis, Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and major basic protein [PRG2 [proteoglycan 2, pro eosinophil major basic protein]], enzyme-linked immunosorbent assays (ELISA) specimen obtained by esophageal string test, algorithm reported as probability of active or inactive eosinophilic esophagitis | Esophageal String Test™ (EST) by Cambridge Biomedical, Inc. |
| 0096U | Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine | HPV, High-Risk, Male Urine by Molecular Testing Labs |
| 0105U | Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, | KidneyIntelXTM, RenalytixAI |

| | | |
|-------|--|---|
| | TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD) | |
| 0107U | Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method | Singulex Clarity C.diff toxins A/B assay by Singulex |
| 0108U | Gastroenterology (Barrett's esophagus), whole slide—digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer | TissueCypher® Barrett's Esophagus Assay by Cernostics |
| 0109U | Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species | MYCODART Dual Amplification Real Time PCR Panel for 4 Aspergillus species, RealTime Laboratories, Inc/MycoDART, Inc |
| 0110U | Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected | Oral OncolyticAssuranceRX, Firstox Laboratories, LLC |
| 0112U | Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene | MicroGenDX qPCR & NGS for Infection, MicroGenDX |
| 0114U | Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus | EsoGuard™ by Lucid Diagnostics |
| 0115U | Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | ePlex Respiratory Pathogen (RP) Panel, GenMark Diagnostics, Inc |
| 0116U | Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications | Snapshot Oral Fluid Compliance, Ethos Laboratories |
| 0117U | Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, | Foundation PI SM by Ethos Laboratories |

| | | |
|------------------|---|--|
| | kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain | |
| 0118U | Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA | Viracor TRACTM dd-cfDNA, Viracor Eurofins |
| 0121U | Fetal congenital abnormalities, biochemical assays of 3 analytes (free beta-hCG, PAPP-A, AFP), time-resolved fluorescence immunoassay, maternal dried-blood spot, algorithm reported as risk scores for fetal trisomies 13/18 and 21 | Flow Adhesion of Whole Blood on VCAM-1 (FAB-V) by Functional Fluidics |
| 0122U | Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood | Flow Adhesion of Whole Blood to P-SELECTIN (WB-PSEL), by Functional Fluidics |
| 0123U | Mechanical fragility, RBC, shear stress and spectral analysis profiling | Mechanical Fragility, RBC by shear stress profiling and spectral analysis by Functional Fluidics |
| 0136U | ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure) | +RTMinsight™ for ATM by Ambry Genetics |
| 0140U | Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected | |
| 0141U | Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected | |
| 0142U | Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected | |
| 0151U | TERMED 3/31/2022 Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 33 targets, real-time semi-quantitative PCR, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results | |

| | | |
|-------|---|---|
| 0152U | Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens | Karius® Test by Karius |
| 0156U | Copy number (eg, intellectual disability, dysmorphology), sequence analysis | SMASH™ Genomic Assay by Marvel Genomics® |
| 0164U | Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results | IBSchek®, Commonwealth Diagnostics International, Inc |
| 0166U | Liver disease, 10 biochemical assays (α 2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation | LiverFAST™, Fibronostics |
| 0167U | Gonadotropin, chorionic (hCG), immunoassay with direct optical observation, blood | ADEXUSDx hCG Test, NOWDiagnostics |
| 0170U | Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis | Clarifi™, Quadrant Biosciences, Inc |
| 0174U | Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents | LC-MS/MS Targeted Proteomic Assay, OncoOmicDx Laboratory, LDT |
| 0176U | Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA) | IBSchek®, Commonwealth Diagnostics International, Inc |
| 0206U | Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease | DISCERN, NeuroDiagnostics, |
| 0207U | Disease quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) | DISCERN, NeuroDiagnostics, |
| 0210U | Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR) | BioPlex 2200 RPR Assay - Quantitative, Bio-Rad Laboratories |
| 0219U | Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], | Sentosa® SQ HIV-1 Genotyping Assay, Vela Diagnostics USA, |

| | | |
|-------|---|---|
| | reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility | |
| 0220U | Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score | PreciseDx™ Breast Cancer Test, PreciseDx, PreciseDx |
| 0243U | Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia | PIGF Preeclampsia Screen, PerkinElmer |
| 0247U | Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth | PreTRM®, Sera Prognostics, Sera Prognostics, Inc® |
| 0251U | Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma | Intrinsic Hepcidin IDx™ Test, IntrinsicDx, Intrinsic LifeSciences™ |
| 0255U | Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score | Cap-Score™ Test, Androvia LifeSciences Lab |
| 0259U | Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative | GFR by NMR, Labtech™ Diagnostics |
| 0261U | Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score | Immunoscore®, HalioDx, HalioDx |
| 0262U | Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffinembedded (FFPE), algorithm reported as gene pathway activity score | OncoSignal 7 Pathway Signal, Protean BioDiagnostics, Philips Electronics Nederland BV |
| 0263U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, ?ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), | NPDX ASD and Central Carbon Energy Metabolism, Stemina Biomarker Discovery, Inc. |

| | | |
|-------|---|---|
| | plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD) | |
| 0311U | Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)–based antimicrobial susceptibility for each organism identified | Accelerate PhenoTest® BC kit, AST configuration, Accelerate Diagnostics, Inc. |
| 0312U | Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment | Avise® Lupus, Exagen Inc. |
| 0316U | Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine | |
| 0322U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD | NPDX ASD Test Panel III, NeuroPointDX |
| 0344U | Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH | OWLiver®, CIMA Sciences, LLC |
| 0346U | Beta amyloid, Aβ40 and Aβ42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma | QUEST AD-Detect™, Beta-Amyloid 42/40 Ratio, Plasma Quest Diagnostics |
| 0351U | Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infection | MeMed BV®, MeMed Diagnostics, Ltd |
| 0352U | Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis–associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected | Xpert® Xpress MVP, Cepheid® |

| | | |
|-------|---|---|
| 0357U | TERMED 9/30/2023 Oncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents | DAWN™ IQ Melanoma, InterVenn Biosciences, California |
| 0358U | Neurology (mild cognitive impairment), analysis of β -amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative | Lumipulse® G β -Amyloid Ratio (1-42/1-40) Test, Fujirebio Diagnostics, Inc., Pennsylvania |
| 0361U | Neurofilament light chain, digital immunoassay, plasma, quantitative | Neurofilament Light Chain (NfL), Mayo Clinic |
| 0369U | Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique | GI assay (Gastrointestinal Pathogen with ABR), Thermo Fisher Scientific |
| 0370U | Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab | Lesion Infection (Wound), Lab Genomics LLC, Thermo Fisher Scientific |
| 0371U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine | Qlear UTI – Reflex ABR, Lifescan Labs of Illinois, Thermo Fisher Scientific |
| 0372U | Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score | Qlear UTI – Reflex ABR, Lifescan Labs of Illinois, Thermo Fisher Scientific |
| 0373U | Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen | Respiratory Pathogen with ABR (RPX), Lab Genomics LLC, Thermo Fisher Scientific |
| 0374U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine | Urogenital Pathogen with Rx Panel (UPX), Lab Genomics LLC, Thermo Fisher Scientific |
| 0376U | Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate | ArteraAI Prostate Test, Artera Inc©, Artera Inc© |

| | | |
|------------------|---|--|
| | cancer-specific mortality, includes predictive algorithm to androgen deprivation therapy response, if appropriate | |
| 0384U | Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LCMS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease | NaviDKDTM Predictive Diagnostic Screening for Kidney Health, Journey Biosciences, Inc, Journey Biosciences, Inc |
| 0385U | Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease | PromarkerD, Sonic Reference Laboratory, Proteomics International Pty Ltd |
| 0386U | TERMED 9/30/2023 Gastroenterology (Barrett's esophagus), P16, RUNX3, HPP1, and FBN1 methylation analysis, prognostic and predictive algorithm reported as a risk score for progression to high-grade dysplasia or esophageal cancer | Envisage, Capsulomics, Inc, Capsulomics, Inc. |
| 0219T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical | TruFUSE® by miniSURG™ Corp. |
| 0220T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic | |
| 0221T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar | |
| 0222T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure) | |
| 0335T | Extra-osseous subtalar joint implant for talotarsal stabilization | |
| 0338T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral | Symplicity Renal Denervation (RDN) System by Medtronic/ EnligHTN multi-electrode renal denervation system by St. Jude Medical/ One-Shot Renal Denervation System |

| | | |
|-------|--|---|
| | | by Covidien/ Vessix Renal Denervation System by Boston Scientific/ CARTO Thermocool Smarttouch Catheter by Biosense Webster |
| 0339T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral | Symlicity Renal Denervation (RDN) System by Medtronic/ EnligHTN multi-electrode renal denervation system by St. Jude Medical/ One-Shot Renal Denervation System by Covidien/ Vessix Renal Denervation System by Boston Scientific/ CARTO Thermocool Smarttouch Catheter by Biosense Webster |
| 0378T | Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional | ForeseeHome age-related macular degeneration Monitoring Program by Notal Vision, Ltd. |
| 0379T | Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional | ForeseeHome age-related macular degeneration Monitoring Program by Notal Vision, Ltd. |
| 0394T | High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed | |
| 0395T | High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed | |
| 0408T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0409T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when | Cardiac Contractility Modulation (CCM) |

| | | |
|-------|---|---|
| | performed, and programming of sensing and therapeutic parameters; pulse generator only | System by Impulse Dynamics |
| 0410T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0411T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0412T | Removal of permanent cardiac contractility modulation system; pulse generator only | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0413T | Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular) | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0414T | Removal and replacement of permanent cardiac contractility modulation system pulse generator only | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0415T | Repositioning of previously implanted cardiac contractility modulation transvenous electrode (atrial or ventricular lead) | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0416T | Relocation of skin pocket for implanted cardiac contractility modulation pulse generator | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0417T | Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0418T | Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system | Cardiac Contractility Modulation (CCM) System by Impulse Dynamics |
| 0422T | Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral | Breastview Visual Mapping System by Medical Tactile, Inc. iBreast Exam (iBE) by UE LifeSciences Inc. |

| | | |
|-------|---|---|
| 0444T | Initial placement of a drug-eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral | Dextenza by Ocular Therapeutix, Inc. |
| 0445T | Subsequent placement of a drug-eluting ocular insert under one or more eyelids, including re-training, and removal of existing insert, unilateral or bilateral | Dextenza by Ocular Therapeutix, Inc. |
| 0449T | Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device | AqueSys XEN® Gel Stent by Allergan |
| 0450T | Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; each additional device (List separately in addition to code for primary procedure) | AqueSys XEN® Gel Stent by Allergan |
| 0499T | Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed | |
| 0507T | Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report | LipiScan Dynamic Meibomian Imager by TearScience |
| 0525T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor) | AngelMed Guardian System by Angel Medical Systems |
| 0526T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only | AngelMed Guardian System by Angel Medical Systems |
| 0527T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only | AngelMed Guardian System by Angel Medical Systems |
| 0528T | Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report | AngelMed Guardian System by Angel Medical Systems |
| 0529T | Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report | AngelMed Guardian System by Angel Medical Systems |
| 0530T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor) | AngelMed Guardian System by Angel Medical Systems |
| 0531T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only | AngelMed Guardian System by Angel Medical Systems |
| 0532T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only | AngelMed Guardian System by Angel Medical Systems |

| | | |
|-------|---|---|
| 0546T | Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report | |
| 0559T | Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure | |
| 0560T | Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure) | |
| 0561T | Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide | |
| 0562T | Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure) | |
| 0569T | Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis | Abbot TriClip Transcatheter Tricuspid Valve Repair System |
| 0570T | Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure) | Abbot TriClip Transcatheter Tricuspid Valve Repair System |
| 0571T | Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed | |
| 0572T | Insertion of substernal implantable defibrillator electrode | |
| 0573T | Removal of substernal implantable defibrillator electrode | |
| 0574T | Repositioning of previously implanted substernal implantable defibrillator-pacing electrode | |
| 0575T | Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional | |
| 0576T | Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter | |
| 0577T | Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes | |

| | | |
|-------|---|--|
| | defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters) | |
| 0578T | Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | |
| 0579T | Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | |
| 0580T | Removal of substernal implantable defibrillator pulse generator only | |
| 0581T | Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral | |
| 0582T | Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance | |
| 0583T | Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia | |
| 0594T | Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device | FITBONE System PRECICE UNYTE Nail |
| 0598T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity) | MolecuLight i:X |
| 0599T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure) | MolecuLight i:X |
| 0602T | Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent | MediBeacon's Transdermal GFR Measurement System and patented pharmaceutical Lumitrace |
| 0603T | Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours | MediBeacon's Transdermal GFR Measurement System and patented |

| | | |
|-------|--|-----------------------------|
| | | pharmaceutical Lumitrace |
| 0604T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-up and patient education on use of equipment | Home OCT (Notal Vision) |
| 0605T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days | Home OCT (Notal Vision) |
| 0606T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days | Home OCT (Notal Vision) |
| 0607T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment | |
| 0608T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional | |
| 0609T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs | NOCISCAN™ Suite (Nocimed) |
| 0610T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis | NOCISCAN™ Suite (Nocimed) |
| 0611T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs | NOCISCAN™ Suite (Nocimed) |
| 0612T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report | NOCISCAN™ Suite (Nocimed) |

| | | |
|-------|---|--|
| 0613T | Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed | InterAtrial Shunt Device (IASD), Corvia Medical |
| 0614T | Removal and replacement of substernal implantable defibrillator pulse generator | Extravascular Implantable Cardioverter Defibrillator system, Medtronic |
| 0615T | Eye-movement analysis without spatial calibration, with interpretation and report | EyeBOX exam, Oculogica |
| 0616T | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens | CustomFlex Artificial Iris, Human Optics |
| 0617T | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with removal of crystalline lens and insertion of intraocular lens | CustomFlex Artificial Iris, Human Optics |
| 0618T | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange | CustomFlex Artificial Iris, Human Optics |
| 0621T | Trabeculostomy ab interno by laser | |
| 0622T | Trabeculostomy ab interno by laser; with use of ophthalmic endoscope | |
| 0623T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report | |
| 0624T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission | |
| 0625T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography | |
| 0626T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report | |
| 0631T | Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and | |

| | | |
|-------|---|--|
| | tissue oxygenation, with interpretation and report, per extremity | |
| 0632T | Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance | |
| 0639T | Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed | |
| 0643T | Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach | Revivent TC System - BioVentric |
| 0640T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition, interpretation and report, each flap or wound | |
| 0641T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition only, each flap or wound | |
| 0642T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); interpretation and report only, each flap or wound | |
| 0644T | Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed | AngioVac System |
| 0645T | Transcatheter implantation of coronary sinus reduction device including vascular access and closure, right heart catheterization, venous angiography, coronary sinus angiography, imaging guidance, and supervision and interpretation, when performed | Neovasc Reducer |
| 0646T | Transcatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed | Intrepid Transcatheter Mitral Valve Replacement System (Medtronic) |
| 0647T | Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report | Puma-G System (Ultrasound Gastronomy) |
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging | Visualase Laser Ablation, Medtronic |

| | | |
|-------|--|--------------------------------------|
| 0656T | Vertebral body tethering, anterior; up to 7 vertebral segments | |
| 0657T | Vertebral body tethering, anterior; 8 or more vertebral segments | |
| 0658T | Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score | Nevisense, SciBase |
| 0659T | Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation | TherOx Downstream System, TherOx Inc |
| 0660T | Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach | |
| 0661T | Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant | |
| 0673T | Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance | |
| 0674T | Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s) | |
| 0675T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead | |
| 0676T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure) | |
| 0677T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead | |
| 0678T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure) | |
| 0679T | Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | |

| | | |
|-------|---|--|
| 0680T | Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s) | |
| 0681T | Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads | |
| 0682T | Removal of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | |
| 0683T | Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | |
| 0684T | Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | |
| 0685T | Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | |
| 0687T | Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session | |
| 0688T | Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month | |
| 0689T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) | |
| 0690T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure) | |
| 0691T | Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone | |

| | | |
|-------|---|--|
| | density when performed, data preparation, interpretation, and report | |
| 0693T | Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report | |
| 0695T | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement | |
| 0696T | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation | |
| 0697T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; multiple organs | |
| 0698T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure) | |
| 0700T | Molecular fluorescent imaging of suspicious nevus; first lesion | |
| 0701T | Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure) | |
| 0704T | Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment | |
| 0705T | Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days | |
| 0706T | Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month | |
| 0707T | Injection(s), bone-substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including | |

| | | |
|-------|---|------------------------|
| | imaging guidance and arthroscopic assistance for joint visualization | |
| 0715T | Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure) | |
| 0716T | Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score | |
| 0725T | Vestibular device implantation, unilateral | |
| 0726T | Removal of implanted vestibular device, unilateral | |
| 0727T | Removal and replacement of implanted vestibular device, unilateral | |
| 0728T | Diagnostic analysis of vestibular implant, unilateral; with initial programming | |
| 0729T | Diagnostic analysis of vestibular implant, unilateral; with subsequent programming | |
| 0730T | Trabeculotomy by laser, including optical coherence tomography (OCT) guidance | ExTra ELT by ELT Sight |
| 0731T | Augmentative AI-based facial phenotype analysis with report | |
| 0732T | Immunotherapy administration with electroporation, intramuscular | |
| 0733T | Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days | |
| 0734T | Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; treatment management services by a physician or other qualified health care professional, per calendar month | |
| 0735T | Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure) | |
| 0736T | Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter | |
| 0737T | Xenograft implantation into the articular surface | |
| 0738T | Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination | |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation | |
| 0743T | Bone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and BMD and | |

| | | |
|-------|---|--|
| | classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report | |
| 0744T | Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed | |
| 0748T | Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings) | |
| 0764T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure) | |
| 0765T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram | |
| 0770T | Virtual reality technology to assist therapy (List separately in addition to code for primary procedure) | |
| 0771T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | |
| 0772T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service) | |
| 0773T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older | |
| 0774T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service | |

| | | |
|-------|---|-------------------|
| | that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service) | |
| 0777T | Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure) | |
| 0778T | Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function | |
| 0779T | Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report | |
| 0781T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi | |
| 0782T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus | |
| 0791T | Motor-cognitive, semi-immersive virtual reality–facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure) | |
| 0793T | Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance | |
| 0794T | Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately | CureMatch therapy |
| 0795T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; complete system (ie, right atrial and right ventricular pacemaker components) | |
| 0796T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system) | |

| | | |
|-------|---|--|
| 0797T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | |
| 0798T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (ie, right atrial and right ventricular pacemaker components) | |
| 0799T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component | |
| 0800T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | |
| 0801T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; dual-chamber system (ie, right atrial and right ventricular pacemaker components) | |
| 0802T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component | |
| 0803T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | |
| 0804T | Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, | |

| | | |
|-------|--|---|
| | with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers | |
| 0805T | Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); percutaneous femoral vein approach | |
| 0806T | Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); open femoral vein approach | |
| 0807T | Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report | XV Lung Ventilation Analysis Software |
| 0808T | Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report | XV Lung Ventilation Analysis Software |
| 0387U | Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression | AMBLor melanoma prognostic test, Avero® Diagnostics |
| 0390U | Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score | PEPredictDx, OncoOmicsDx Laboratory, mProbe |
| 0393U | Neurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded α -synuclein protein by seed amplification assay, qualitative | SYNTap Biomarker Test, Amprion Clinical Laboratory, Amprion Clinical Laboratory |
| 0394U | Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 16 PFAS compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative | PFAS Testing & PFASure, National Medical Services, NMS Labs, Inc |
| 0398U | Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer | ESOPREDICT Barrett's Esophagus Risk Classifier Assay, Capsulomics, Inc |
| 0399U | Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgGbinding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected | FRAT (Folate Receptor Antibody Test), Religen Inc |

| | | |
|-------|--|--|
| 57465 | Computer-aided mapping of cervix uteri during colposcopy, including optical dynamic spectral imaging and algorithmic quantification of the acetowhitening effect (List separately in addition to code for primary procedure) | DYSIS Medical digital colposcope |
| 62263 | Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days | |
| 62264 | Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day | |
| 64910 | Nerve repair; with synthetic conduit or vein allograft (eg, nerve tube), each nerve | |
| 68841 | Insertion of drug-eluting implant, including punctal dilation when performed, into lacrimal canaliculus, each | |
| 77089 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-ris | |
| 77090 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere | |
| 77091 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only | |
| 77092 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional | |
| 77423 | High energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s) | |
| 81506 | Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score | Boston Heart Prediabetes Assessment PreDx Diabetes Risk Score (DRS) by Tethys Bioscience, Inc |
| 83951 | Oncoprotein; des-gamma-carboxy-prothrombin (DCP) | |
| 93590 | Percutaneous transcatheter closure of paravalvular leak; initial occlusion device, mitral valve | |
| 93591 | Percutaneous transcatheter closure of paravalvular leak; initial occlusion device, aortic valve | |

| | | |
|--------------------|--|--|
| 95919 | Quantitative pupillometry with physician or other qualified health care professional interpretation and report, unilateral or bilateral | |
| 96931 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, first lesion | VivaScope 1500 by Caliber Imaging & Diagnostics, Inc. |
| 96932 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, first lesion | VivaScope 1500 by Caliber Imaging & Diagnostics, Inc. |
| 96933 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, first lesion | VivaScope 1500 by Caliber Imaging & Diagnostics, Inc. |
| 96934 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, each additional lesion (List separately in addition to code for primary procedure) | VivaScope 1500 by Caliber Imaging & Diagnostics, Inc. |
| 96935 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, each additional lesion (List separately in addition to code for primary procedure) | VivaScope 1500 by Caliber Imaging & Diagnostics, Inc. |
| 96936 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, each additional lesion (List separately in addition to code for primary procedure) | VivaScope 1500 by Caliber Imaging & Diagnostics, Inc. |
| 97610 | Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day | |
| HCPCS CODES | | |
| A6000 | Non-contact wound warming wound cover for use with the non-contact wound warming device and warming card | |
| A9268 | Programmer for transient, orally ingested capsule | Vibrant System |
| A9269 | Programable, transient, orally ingested capsule, for use with external programmer, per month | Vibrant System |
| A9292 | Prescription digital visual therapy, software-only, FDA cleared, per course of treatment | Luminopia One |
| C1761 | Catheter, transluminal intravascular lithotripsy, coronary | Shockwave Coronary Rx Lithoplasty System |
| C1824 | Generator, cardiac contractility modulation (implantable) | Cardiac Contractility Modulation for Chronic Heart Failure (i.e., Optimizer by Impulse Dynamics) |
| C1833 | Monitor, cardiac, including intracardiac lead and all system components (implantable) | |
| C9352 | Microporous collagen implantable tube (neuragen nerve guide), per centimeter length | |

| | | |
|-------|---|--|
| C9353 | Microporous collagen implantable slit tube (neurawrap nerve protector), per centimeter length | |
| C9355 | Collagen nerve cuff (neuromatrix), per 0.5 centimeter length | |
| C9759 | Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed | Bullfrog Micro-infusion device by Mercator Medsystems |
| C9787 | Gastric electrophysiology mapping with simultaneous patient symptom profiling | |
| C9790 | Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including image guidance | |
| C9361 | Collagen matrix nerve wrap (neuromend collagen nerve wrap), per 0.5 centimeter length | |
| C9764 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |
| C9765 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |
| C9766 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |
| C9767 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |
| C9768 | Endoscopic ultrasound-guided direct measurement of hepatic portosystemic pressure gradient by any method (list separately in addition to code for primary procedure) | Echotip by Cook Medical |
| C9771 | Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral | Clarifix by Stryker Inc. |
| C9772 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel (s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |
| C9773 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |
| C9774 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel (s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |

| | | |
|-------|--|--|
| C9775 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel (s), when performed | Shockwave Medical Peripheral IVL System by Shockwave Medical Inc |
| C9780 | Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance | Surfacer® Inside-Out® Access Catheter System (Surfacer System) |
| C9781 | Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed | InSpace Subacromial Spacer by Stryker |
| E0231 | Non-contact wound warming device (temperature control unit, ac adapter and power cord) for use with warming card and wound cover. | |
| E0232 | Warming card for use with the non contact wound warming device and non contact wound warming wound cover | |
| E0677 | Non-pneumatic sequential compression garment, trunk | Koya Dayspring |
| E1905 | Virtual reality cognitive behavioral therapy device (cbt), including pre-programmed therapy software | RelieVRx by Applied VR |
| G0069 | Professional services for the administration of subcutaneous immunotherapy for each infusion drug administration calendar day in the individual's home, each 15 minutes | |
| J1096 | Dexamethasone, lacrimal ophthalmic insert, 0.1 mg | Dextenza® by Ocular Therapeutix, Inc. |
| J7402 | Mometasone furoate sinus implant, (sinuva), 10 micrograms | SINUVA |
| K1004 | Low frequency ultrasonic diathermy treatment device for home use | |
| K1007 | Bilateral hip, knee, ankle, foot device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors | ReWalk™ Exoskeleton by ReWalk Robotics |
| K1009 | Speech volume modulation system, any type, including all components and accessories | SpeechVive by SpeechVive Inc. |
| K1030 | External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only | Cardiac Contractility Modulation for Chronic Heart Failure (i.e., Optimizer by Impulse Dynamics) |
| K1031 | Non-pneumatic compression controller without calibrated gradient pressure | |
| K1032 | Non-pneumatic sequential compression garment, full leg | |
| K1033 | Non-pneumatic sequential compression garment, half leg | |
| K1036 | Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month | |

| | | |
|-------|---|-------------------------------------|
| L8701 | Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated | MyoPro® (Myomo, Inc.) Assist Device |
| L8702 | Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated | MyoPro® (Myomo, Inc.) Assist Device |

***Coding Notes:**

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- See the non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#) for additional information.
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

POLICY REVISION HISTORY

| DATE | REVISION SUMMARY |
|---------|---|
| 2/2023 | Converted to new policy template. |
| 3/2023 | Interim update: 4/1 codes. |
| 6/2023 | Annual review. Title update. Defined investigational vs not medically necessary codes. |
| 7/2023 | Q3 2023 code set update. |
| 10/2023 | Q4 2023 code set update. |
| 12/2023 | Interim update. Remove codes 0087U and 0088U from policy, to be addressed in Non-Covered Genetic Testing Panels policy. |